Quince Therapeutics Inc. (QNCX) Financial Statements (2024 and earlier)

Company Profile

Business Address 611 GATEWAY BLVD., SUITE 273
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. CA
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:75,100,00090,200,000106,800,000133,800,00099,900,000
Cash and cash equivalents19,531,00040,593,00029,454,000 51,214,000
Short-term investments54,307,00045,602,00037,078,00066,979,00048,650,000
Other undisclosed cash, cash equivalents, and short-term investments1,262,0004,005,00040,268,00066,821,00036,000
Prepaid expense365,000223,000333,000274,000987,000
Other current assets81,000276,000367,000694,000688,000
Other undisclosed current assets1,894,0003,049,0004,173,0003,094,0004,481,000
Total current assets:77,440,00093,748,000111,673,000137,862,000106,056,000
Noncurrent Assets
Operating lease, right-of-use asset385,000291,0001,165,000674,000625,000
Property, plant and equipment234,000393,000263,000427,000709,000
Long-term investments and receivables  3,578,00019,933,00050,464,00016,763,000
Long-term investments  3,578,00019,933,00050,464,00016,763,000
Intangible assets, net (including goodwill)81,297,0005,900,000   
Goodwill17,625,000    
Intangible assets, net (excluding goodwill)63,672,0005,900,000   
Other noncurrent assets8,456,000 194,00039,000217,000
Other undisclosed noncurrent assets88,000    
Total noncurrent assets:90,460,00010,162,00021,555,00051,604,00018,314,000
TOTAL ASSETS:167,900,000103,910,000133,228,000189,466,000124,370,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,469,0003,069,00014,222,00016,996,0008,892,000
Accounts payable2,033,000570,0004,911,0003,555,0003,075,000
Accrued liabilities3,436,0002,499,0009,311,00013,441,0005,817,000
Business combination, contingent consideration, liability4,103,000    
Total current liabilities:9,572,0003,069,00014,222,00016,996,0008,892,000
Noncurrent Liabilities
Long-term debt and lease obligation:   420,000208,000 
Liabilities, other than long-term debt59,815,000248,000   
Deferred income tax liabilities5,304,000248,000   
Other liabilities587,000    
Operating lease, liability321,000 420,000208,000 
Business combination, contingent consideration, liability53,603,000    
Other undisclosed noncurrent liabilities13,429,000 (420,000)(208,000) 
Total noncurrent liabilities:73,244,000248,000420,000208,000 
Total liabilities:82,816,0003,317,00014,642,00017,204,0008,892,000
Equity
Equity, attributable to parent85,084,000100,593,000118,586,000172,262,000115,478,000
Common stock43,00036,00030,00029,00027,000
Additional paid in capital401,638,000389,105,000355,234,000318,574,000185,196,000
Accumulated other comprehensive income (loss)3,047,000(289,000)(79,000)313,00060,000
Accumulated deficit(319,644,000)(288,259,000)(236,599,000)(146,654,000)(69,805,000)
Total equity:85,084,000100,593,000118,586,000172,262,000115,478,000
TOTAL LIABILITIES AND EQUITY:167,900,000103,910,000133,228,000189,466,000124,370,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(34,620,000)(52,015,000)(90,318,000)(78,893,000)(39,168,000)
Operating loss:(34,620,000)(52,015,000)(90,318,000)(78,893,000)(39,168,000)
Nonoperating income (expense)5,395,000184,000(505,000)1,409,0002,188,000
Investment income, nonoperating5,497,0001,181,000(258,000)1,409,0002,188,000
Other nonoperating expense(102,000)(997,000)(247,000)  
Loss from continuing operations before equity method investments, income taxes:(29,225,000)(51,831,000)(90,823,000)(77,484,000)(36,980,000)
Other undisclosed income (loss) from continuing operations before income taxes(2,357,000)(113,000)878,000  
Loss from continuing operations before income taxes:(31,582,000)(51,944,000)(89,945,000)(77,484,000)(36,980,000)
Income tax expense (benefit)(197,000)284,000   
Loss from continuing operations:(31,779,000)(51,660,000)(89,945,000)(77,484,000)(36,980,000)
Loss before gain (loss) on sale of properties:(89,945,000)(77,484,000)(36,980,000)
Other undisclosed net income394,000  635,000 
Net loss available to common stockholders, diluted:(31,385,000)(51,660,000)(89,945,000)(76,849,000)(36,980,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(31,385,000)(51,660,000)(89,945,000)(76,849,000)(36,980,000)
Comprehensive loss:(31,385,000)(51,660,000)(89,945,000)(76,849,000)(36,980,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,336,000(210,000)(392,000)253,000109,000
Comprehensive loss, net of tax, attributable to parent:(28,049,000)(51,870,000)(90,337,000)(76,596,000)(36,871,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: